Medicus Pharma, a small precision-medicine biotech based just outside Philadelphia in West Conshohocken, has received authorization from the UAE Department of Health – Abu Dhabi to move forward with a Phase 2a study testing its drug Teverelix in women with moderate-to-severe endometriosis. The study, called PRECISION-E2, is built around an approach the company is betting will set it apart from earlier endometriosis trials: pairing the drug trial with genomic analysis from day one instead of bolting genetics on after the fact.
What the Study Actually Tests
PRECISION-E2 is a prospective, randomized, placebo-controlled trial enrolling about 84 women across multiple sites in the UAE. Participants are split evenly into four groups: Teverelix 60mg by subcutaneous injection, Teverelix 90mg subcutaneous, Teverelix 90mg intramuscular, or placebo. The primary endpoint tracks whether patients maintain serum estradiol within what’s known as the Barbieri therapeutic window, 20 to 50 pg/mL, for at least 14 consecutive days after treatment, a range associated with symptom control while limiting the bone density and other side effects that come with driving estrogen too low.
The genomics piece is where the study gets more ambitious. Alongside the usual pharmacokinetic, safety, pain, and quality-of-life measures, the trial will run exploratory genomic analysis on a set of genes including ESR1, ESR2, CYP19A1, GNRHR, FSHR, and LHCGR, integrating whole-genome data with hormonal response and clinical outcomes from the start of the trial rather than as a retrospective add-on. The goal is to start building a dataset that could eventually help predict which patients respond best to which dose and route of administration, instead of treating endometriosis patients as a single uniform population.
Why Teverelix, and Why This Matters
Teverelix is a next-generation, long-acting GnRH antagonist, meaning it suppresses reproductive hormones quickly and reversibly, without the initial hormonal flare-up that comes with older GnRH agonist drugs. As an injectable depot formulation, it’s also designed to allow less frequent dosing than the daily oral GnRH antagonists currently on the market.
That matters because endometriosis is a genuinely underserved disease despite having several approved treatments already. It affects roughly one in ten women of reproductive age worldwide, causing chronic pelvic pain, painful periods, and infertility, and its effects ripple into education, careers, family planning, and mental health. Even with existing therapies available, a lot of patients deal with inadequate symptom control, side effects severe enough to stop treatment, disease recurrence, and wildly inconsistent responses from one patient to the next. That inconsistency is exactly the problem Medicus is trying to attack with the genomics angle, on the theory that some of that variability is written into patients’ DNA and can be predicted rather than discovered through trial and error.
A Small Philadelphia-Area Company With a Global Pipeline
Medicus Pharma, which trades on Nasdaq under MDCX, describes itself as a precision-guided biotech working on novel therapeutic assets across three continents, and this authorization is a good example of what that actually looks like in practice: a company headquartered in the Philadelphia region running a genomics-driven clinical trial in Abu Dhabi. Beyond Teverelix, which is also being developed for advanced prostate cancer in cardiovascular high-risk patients and for acute urinary retention linked to benign prostatic hyperplasia, the company’s pipeline includes SkinJect, a localized immuno-oncology program targeting non-melanoma skin cancers and Gorlin Syndrome.
Dr. Raza Bokhari, Medicus Pharma’s Executive Chairman and CEO, framed the authorization as validation of the company’s broader strategy, not just a single trial clearing a regulatory hurdle: “Today’s IND authorization represents far more than approval to initiate another clinical study, it validates a development strategy designed to combine precision endocrinology, pharmacology and population genomics within a prospective clinical trial.”
That strategy, running lean, advancing programs through Phase 2 proof-of-concept, and then looking for a larger pharma partner to fund late-stage development, is a common playbook for small biotechs. What’s less common is running that playbook with a trial explicitly designed to generate a genomics dataset alongside the clinical results, which, if it works, could make Medicus’s data more valuable to a future partner than the drug alone would be.
